Technical Analysis for HGEN - Humanigen Inc.

Grade Last Price % Change Price Change
grade C 0.88 25.71% 0.1800
HGEN closed up 25.71 percent on Tuesday, October 22, 2019, on 5 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical HGEN trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Narrow Range Bar Range Contraction 25.71%
Wide Bands Range Expansion 25.71%
MACD Bullish Signal Line Cross Bullish 25.71%
Narrow Range Bar Range Contraction 25.71%
Wide Bands Range Expansion 25.71%
Oversold Stochastic Weakness 25.71%

Older signals for HGEN ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Humanigen, Inc., a biopharmaceutical company, engages in developing its proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company's products include lenzilumab and ifabotuzumab, which are monoclonal antibodies derived from Humaneered platform. Lenzilumab targets granulocyte-macrophage colony-stimulating factor (GM-CSF), and is in development as a potential medicine for chimeric antigen receptor T cell (CAR-T) therapy, as well as a potential treatment for rare hematologic cancers, such as chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML). Ifabotuzumab targets Ephrin type-A receptor 3 (EphA3), and is being explored as a potential treatment for glioblastoma multiforme (GBM) and other cancers, as well as for use in novel CAR-T construct and bispecific antibody platform. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was founded in 2000 and is based in Burlingame, California.
Medicine Medical Specialties Clinical Medicine Biopharmaceutical Cancers Antibodies Immune System Immunotherapy Monoclonal Antibodies Cancer Immunotherapy Chimeric Antigen Receptor T Cell Glioblastoma Multiforme
Is HGEN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 1.544
52 Week Low 0.43
Average Volume 3,641
200-Day Moving Average 1.0163
50-Day Moving Average 0.8846
20-Day Moving Average 0.762
10-Day Moving Average 0.7352
Average True Range 0.1358
ADX 18.49
+DI 38.2587
-DI 17.1659
Chandelier Exit (Long, 3 ATRs ) 0.6426
Chandelier Exit (Short, 3 ATRs ) 1.0084
Upper Bollinger Band 0.9771
Lower Bollinger Band 0.5469
Percent B (%b) 0.77
BandWidth 56.456693
MACD Line -0.0431
MACD Signal Line -0.0583
MACD Histogram 0.0152
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.8800
Resistance 3 (R3) 0.8800 0.8800 0.8800
Resistance 2 (R2) 0.8800 0.8800 0.8800 0.8800
Resistance 1 (R1) 0.8800 0.8800 0.8800 0.8800 0.8800
Pivot Point 0.8800 0.8800 0.8800 0.8800 0.8800
Support 1 (S1) 0.8800 0.8800 0.8800 0.8800 0.8800
Support 2 (S2) 0.8800 0.8800 0.8800 0.8800
Support 3 (S3) 0.8800 0.8800 0.8800
Support 4 (S4) 0.8800